08:00 , Mar 10, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Lipoprotein-associated phospholipase A2 (PLA2G7; PAFAH; Lp-PLA2)

Ophthalmic disease INDICATION: Diabetic macular edema (DME) In vitro and rat studies identified a PLA2G7 inhibitor that could help treat DME. Chemical synthesis and in vitro studies of pyrimidone analogs identified a compound that inhibited...
08:00 , Mar 3, 2016 |  BC Innovations  |  Emerging Company Profile

SNP it all together

Genomewide association studies can link SNPs to specific disease phenotypes, but the narrow scope of individual SNP studies limits their power of prediction for targeting the associated genes. Genomics plc is developing a computational platform...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

Diadexus, OriGene deal

Diadexus granted OriGene exclusive rights to develop and commercialize Diadexus’ PLAC ELISA test in undisclosed Asian countries. OriGene purchased $1 million in diaDexus stock at about $3.82 per share, which is about a 27% premimum...
07:00 , Sep 3, 2015 |  BC Innovations  |  Targets & Mechanisms

Low-fat brain

While most of the focus in Alzheimer's disease is on slowing or stopping the degeneration of neurons, a team at the University of Montreal has found that one cause of the disease could lie in...
08:00 , Jan 26, 2015 |  BC Week In Review  |  Clinical News

PLAC Test for Lp-PLA2 Activity regulatory update

Last month, FDA granted 510(k) clearance to the PLAC Test for Lp-PLA2 Activity from diaDexus as an aid in determining risk of coronary heart disease (CHD) in patients with no prior history of cardiovascular events....
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

PLAC Test for Lp-PLA2 Activity regulatory update

diaDexus said FDA accepted for review a 510(k) submission of the company’s PLAC Test for Lp-PLA2 Activity, an enzyme assay for the quantitative determination of lipoprotein-associated phospholipase A2 ( PLA2G7 ; PAFAH ; Lp-PLA2) in...
07:00 , May 19, 2014 |  BC Week In Review  |  Clinical News

Darapladib: Phase III data

Top-line data from the double-blind, international Phase III SOLID-TIMI 52 trial in >13,000 patients who began treatment within 30 days following an ACS showed that once-daily 160 mg oral darapladib plus standard of care (SOC)...
01:30 , May 14, 2014 |  BC Extra  |  Clinical News

GSK's darapladib misses in Phase III ACS trial

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said once-daily oral darapladib ( SB-480848 ) plus standard of care (SOC) missed the primary endpoint vs. placebo plus SOC in the Phase III SOLID-TIMI 52 trial to treat acute coronary...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Clinical News

Darapladib: Additional Phase III data

Additional data from the double-blind, international Phase III STABILITY trial in 15,828 patients with chronic CHD showed that once-daily 160 mg oral darapladib plus standard of care (SOC) met the secondary endpoints of reducing the...
07:00 , Mar 20, 2014 |  BC Innovations  |  Tools & Techniques

Plasma lipids: harbingers of AD?

A panel of plasma lipids could represent a new diagnostic tool for identifying patients likely to develop Alzheimer's disease before symptoms appear, according to new clinical findings from a team of U.S. researchers. 1 Although...